Mouse model of dermal fibrosis induced by one-time injection of bleomycin-poly(L-lactic acid) microspheres

Rheumatology

Volumn 47, Issue 4, 2008, Pages 454-457

  Shibusawa, Y ^a   Negishi, I ^a   Tabata, Y ^b   Ishikawa, O ^a  

^a GUNMA UNIVERSITY   (Japan)

^b KYOTO UNIVERSITY   (Japan)

Author keywords

Bleomycin; Dermal fibrosis; Drug delivery system; Mouse model; Poly(L lactic acid); Scleroderma

Indexed keywords

BLEOMYCIN; COLLAGEN; COLLAGEN TYPE 1ALPHA1; CONNECTIVE TISSUE GROWTH FACTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYLACTIC ACID; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; CCL2 PROTEIN, MOUSE; COLLAGEN TYPE 1; COLLAGEN TYPE I, ALPHA 1 CHAIN; IMMEDIATE EARLY PROTEIN; LACTIC ACID; MESSENGER RNA; MICROSPHERE; SIGNAL PEPTIDE; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; GENE EXPRESSION; HISTOPATHOLOGY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCLERODERMA; SKIN FIBROSIS; ANIMAL; BIOSYNTHESIS; C3H MOUSE; CHEMICALLY INDUCED DISORDER; DELAYED RELEASE FORMULATION; FEMALE; FIBROSIS; GENETICS; METABOLISM; METHODOLOGY; PATHOLOGY; POLYMERASE CHAIN REACTION; SKIN; SUBCUTANEOUS DRUG ADMINISTRATION; SYSTEMIC SCLEROSIS;

ANIMALS; BLEOMYCIN; CHEMOKINE CCL2; COLLAGEN; COLLAGEN TYPE I; DELAYED-ACTION PREPARATIONS; DISEASE MODELS, ANIMAL; FEMALE; FIBROSIS; GENE EXPRESSION; IMMEDIATE-EARLY PROTEINS; INJECTIONS, SUBCUTANEOUS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LACTIC ACID; MICE; MICE, INBRED C3H; MICROSPHERES; POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 43049181995     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ken058     Document Type: Article

References (29)

1. LeRoy EC, Trojanowska M, Smith EA. The pathogenesis of scleroderma (systemic sclerosis, SSc). Clin Exp Rheumatol 1991;9:173-7.
2. Denton CP, Black CM. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90.
3. Lakos G, Takagawa S, Varga J. Animal models of scleroderma. Methods Mol Med 2004;102:377-93.
4. Clark SH. Animal models in scleroderma. Curr Rheumatol Rep 2005;7:150-5.
5. Mori T, Kawara S, Shinozaki M et al. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: A mouse fibrosis model. J Cell Physiol 1999;181:153-9.
6. Ruzek MC, Jha S, Ledbetter S, Richards SM, Garman RD. A modified model of graftversus-host-induced systemic sclerosis (scleroderma) exhibits all major aspects of the human disease. Arthritis Rheum 2004;50:1319-31.
7. Samuel CS, Zhao C, Yang Q et al. The relaxin gene knockout mouse: a model of progressive scleroderma. J Invest Dermatol 2005;125:692-9.
8. Yamamoto T, Takagawa S, Katayama I et al. Animal model of sclerotic skin. I: Local injections of bleomycin induce sclerotic skin mimicking scleroderma. J Invest Dermatol 1999;112:456-62.
9. Nakase H, Okazaki K, Tabata Y et al. Development of an oral drug delivery system targeting immune-regulating cells in experimental inflammatory bowel disease: A new therapeutic strategy. J Pharmacol Exp Ther 2000;292:15-21.
10. Yamamoto T. Experimental mouse model of scleroderma: Induction by bleomycin. In: Lawrence SC, ed. Animal models of human inflammatory skin diseases. CRC Press: Boca Raton, 2004;535-47.
11. Yamamoto T. The bleomycin-induced scleroderma model: What have we learned for scleroderma pathogenesis? Arch Dermatol Res 2006;297:333-4.
12. Yamamoto T, Kuroda M, Nishioka K. Animal model of sclerotic skin. III: Histopathological comparison of bleomycin-induced scleroderma in various mice strains. Arch Dermatol Res 2000;292:535-41.
13. Jalil R, Nixon JR. Biodegradable poly(lactic acid) and poly(lactide-co-glycolide) microcapsules: Problems associated with preparative techniques and release properties. J Microencapsul 1990;7:297-325.
14. Tabata Y, Ikada Y. Drug delivery system for antitumor activation of macrophages. Crit Rev Ther Drug Carrier Syst 1990;7:121-48.
15. Tabata Y, Ikada Y. Macrophage phagocytosis of biodegradable microspheres composed of L-lactic/glycolic acid homo- and copolymers. J Biomed Mater Res 1988;22:837-58.
16. Wu XS. Preparation, characterization, and drug delivery applications of microspheres based on biodegradable lactic/glycolic acid polymers. In: Wise DL, Trantolo DJ, Altobelli DE et al., eds. Encyclopedic handbook of biomaterials and bioengineering. New York: Marcel Dekker, 1885;1151-200.
17. Wu XS. Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Wise DL, Trantolo DJ, Altobelli DE et al., eds. Encyclopedic handbook of biomaterials and bioengineering. New York: Marcel Dekker, 1995;1015-4.
18. Amecke B, Bendix D, Entenmann G. Synthetic resorbable polymers based on glycolide, lactides, and similar monomers. In: Wise DL, Trantolo DJ, Altobelli DE et al., eds. Encyclopedic handbook of biomaterials and bioengineering. New York: Marcel Dekker, 1995;977-1007.
19. Anderson JM, Shive MS. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997;28:5-24.
20. Rollins BJ. Monocyte chemoattractant protein 1. A potential regulator of monocyte recruitment in inflammatory disease. Mol Med Today 1996;2:198-204.
21. Antoniades HN, Neville-Golden J, Galanopoulos T, Kradin RL, Valente AJ, Graves DT. Expression of monocyte chemoattractant protein 1 mRNA in human idiopathic pulmonary fibrosis. Proc Natl Acad Sci USA 1992;89:5371-5.
22. Distler O, Pap T, Kowal-Bielecka O et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: Role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum 2001;44:2665-78.
23. Wada T, Furuichi K, Segawa-Takaeda C et al. MIP-1alpha and MCP-1 contribute to crescents and interstitial lesions in human crescentic glomerulonephritis. Kidney Int 1999;56:995-1003.
24. Yamamoto T, Nishioka K. Role of monocyte chemoattractant protein-1 and its receptor,CCR-2, in the pathogenesis of bleomycin-induced scleroderma. J Invest Dermatol 2003;121:510-6.
25. Ferreira AM, Takagawa S, Fresco R, Zhu X, Varga J, DiPietro LA. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J Invest Dermatol 2006;126:1900-8.
26. Ihn H. Scleroderma, fibroblasts, signaling, and excessive extracellular matrix. Curr Rheumatol Rep 2005;7:156-62.
27. Oi M, Yamamoto T, Nishioka K. Increased expression of TGF-beta1 in the sclerotic skin in bleomycin-'susceptible' mouse strains. J Med Dent Sci 2004;51:7-17.
28. Blom IE, Goldschmeding R, Leask A. Gene regulation of connective tissue growth factor: New targets for antifibrotic therapy? Matrix Biol 2002;21:473-82.
29. Takehara K. Hypothesis: Pathogenesis of systemic sclerosis. J Rheumatol 2003;30:755-9.